This active molecular is a selective pan-TRK inhibitor. GNE-8525 shows potent antiproliferation activity (IC50 = 0.003 μM) and it shows in vivo antitumor efficacy in tumor xenograft model derived from the KM12 cell line. TRKA are believed to be the key oncogenic driver in many tumors including glioblastoma, melanoma and so on.
Structure of 1196546-33-4
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| 50 mg | $838 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
What is the pharmacokinetics of GNE-8525?
GNE-8525 exhibits moderate in vivo plasma clearances, moderate volumes of distribution, short half-lives, and brain penetration.
27/1/2016
What is the activity of GNE-8525 in vitro?
GNE-8525 has kinase selectivity for MKK4, MKK7, JNK1, JNK2, JNK3, MLK1, MLK2 and MLK3 with IC50 values of >5000 nM, >5000 nM, 129 nM, 514 nM, 364 nM, 67.8 nM, 767 nM and 602 nM, respectively.
20/6/2016
GNE-8525 suppresse CYP-induced nociceptive behavior?
GNE-8525 suppresses CYP-induced nociceptive behavior by inhibiting DLK in mice.
6/12/2018
suppresses CYP-induced edema and hemorrhage
GNE-8525 do well in suppressing CYP-induced edema and hemorrhage in mouse bladder. Very useful for our study!
8/1/2019
display concentration-dependent protection of neurons from degeneration
GNE-8525 displays concentration-dependent protection of neurons from degeneration in vitro. Satisfied with product.
21/12/2021
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.